Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Parkinson's Disease: Treatment01:24

Parkinson's Disease: Treatment

264
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
264
EPS and iPS Cells in Disease Research01:21

EPS and iPS Cells in Disease Research

2.8K
Embryonic and induced pluripotent stem cells are excellent models for disease research because of their ability to self-renew and differentiate into most cell types. Somatic cells from a patient are isolated and reprogrammed into induced pluripotent stem cells or iPSCs. These iPSCs are later differentiated into the desired cell type, which mirrors the diseased cell of the patient. In this way, disease models have been created for investigating diseases such as Down syndrome, type I diabetes,...
2.8K
Parkinson's Disease: Overview01:15

Parkinson's Disease: Overview

541
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
541
Somatic to iPS Cell Reprogramming01:29

Somatic to iPS Cell Reprogramming

2.2K
Reprogramming alters the gene expression in somatic cells, transforming them into induced pluripotent stem (iPS) cells over several generations. Scientists can reprogram cells by introducing genes for four transcription factors—Oct4, Sox2, Klf4, and c-Myc (OSKM) by viral or non-viral methods. These factors are also known as Yamanaka factors after Shinya Yamanaka, who first generated iPS cells using mouse skin cells. Yamanaka was awarded the Nobel Prize in Physiology or Medicine in 2012...
2.2K
iPS Cell Differentiation01:22

iPS Cell Differentiation

2.7K
The ability of induced pluripotent stem cells or iPSCs to differentiate into most body cell types has stimulated repair and regenerative medicine research over the past few decades. iPSC-derived blood cells, hepatocytes, beta islet cells, cardiomyocytes, neurons, and other cell types can repair injuries or regenerate damaged tissue in diseases such as diabetes and neurodegenerative disorders.
2.7K
Methods of Nuclear Reprogramming01:24

Methods of Nuclear Reprogramming

1.8K
Nuclear reprogramming is a process of transforming one cell type into an unrelated cell type by epigenetic changes that alter the cell’s original gene expression pattern. Such epigenetic changes force cells to express a different set of genes, which play a significant role in inducing transformation into other cell types. Nuclear reprogramming offers applications in reproductive cloning for livestock propagation and regenerative medicine — developing patient-specific cells for...
1.8K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Endovascular treatment and outcome in patients with CTP-defined extra-large infarct core stroke.

Journal of neurointerventional surgery·2026
Same author

CRKL amplification synergizes with mechanical stress-induced signaling to dually activate YAP oncogenic pathways, driving plantar melanoma progression.

Apoptosis : an international journal on programmed cell death·2026
Same author

Soft chiral-bridged binuclear Pt(II) complexes with cyclometalated N-heterocyclic carbene ligands for multicolor circularly polarized luminescence.

Chemical communications (Cambridge, England)·2026
Same author

Sustainable Synthesis of Ammonium Nitrate From Air and Water via Tandem Plasma-Electrolyzer System.

Angewandte Chemie (International ed. in English)·2026
Same author

Expression patterns and proliferative effect of OTUD6A on Sertoli cells and Leydig cells in cattleyak.

Theriogenology·2026
Same author

Involvement of sucrose transporter SUT4 in regulating tomato yield and fruit quality.

Plant science : an international journal of experimental plant biology·2026
Same journal

Corrigendum: Neurodegenerative diseases and immune system: From pathogenic mechanism to therapy.

Neural regeneration research·2026
Same journal

Injury and repair in limb deformities associated with peripheral neuropathy: Visualization analyses of research trends and hotspots.

Neural regeneration research·2026
Same journal

Circulating exosomes convey the cognitive benefits of Tai Chi: The role of miR-625-5p in prefrontal remodeling and therapeutic potential.

Neural regeneration research·2026
Same journal

Induced neural stem cells in neuroregeneration: Progress and clinical prospects.

Neural regeneration research·2026
Same journal

Locus coeruleus-norepinephrine system dysfunction: A new concept in cognitive aging and neurodegenerative diseases.

Neural regeneration research·2026
Same journal

The casual explanations of non-coding risk variants in Alzheimer's disease: From single mutation to lipid dysregulation.

Neural regeneration research·2026
See all related articles

Related Experiment Video

Updated: Jun 29, 2025

Generation of Induced Neural Stem Cells from Peripheral Mononuclear Cells and Differentiation Toward Dopaminergic Neuron Precursors for Transplantation Studies
12:13

Generation of Induced Neural Stem Cells from Peripheral Mononuclear Cells and Differentiation Toward Dopaminergic Neuron Precursors for Transplantation Studies

Published on: July 11, 2019

7.2K

Cell reprogramming therapy for Parkinson's disease.

Wenjing Dong1,2, Shuyi Liu1,2, Shangang Li1,2

  • 1State Key Laboratory of Primate Biomedical Research, Institute of Primate Translational Medicine, Kunming University of Science and Technology, Kunming, Yunnan Province, China.

Neural Regeneration Research
|March 25, 2024
PubMed
Summary
This summary is machine-generated.

Cell reprogramming offers a promising new avenue for Parkinson's disease treatment by regenerating lost neurons. Strategies like induced pluripotent stem cells and direct reprogramming show potential, addressing limitations of earlier therapies.

More Related Videos

Chemogenetic Regulation in Reprogrammed Stem Cell-derived Precursor Cells in Treating Neurodegenerative Diseases
09:44

Chemogenetic Regulation in Reprogrammed Stem Cell-derived Precursor Cells in Treating Neurodegenerative Diseases

Published on: May 2, 2025

153
In vitro Modeling for Neurological Diseases using Direct Conversion from Fibroblasts to Neuronal Progenitor Cells and Differentiation into Astrocytes
11:42

In vitro Modeling for Neurological Diseases using Direct Conversion from Fibroblasts to Neuronal Progenitor Cells and Differentiation into Astrocytes

Published on: June 10, 2021

4.9K

Related Experiment Videos

Last Updated: Jun 29, 2025

Generation of Induced Neural Stem Cells from Peripheral Mononuclear Cells and Differentiation Toward Dopaminergic Neuron Precursors for Transplantation Studies
12:13

Generation of Induced Neural Stem Cells from Peripheral Mononuclear Cells and Differentiation Toward Dopaminergic Neuron Precursors for Transplantation Studies

Published on: July 11, 2019

7.2K
Chemogenetic Regulation in Reprogrammed Stem Cell-derived Precursor Cells in Treating Neurodegenerative Diseases
09:44

Chemogenetic Regulation in Reprogrammed Stem Cell-derived Precursor Cells in Treating Neurodegenerative Diseases

Published on: May 2, 2025

153
In vitro Modeling for Neurological Diseases using Direct Conversion from Fibroblasts to Neuronal Progenitor Cells and Differentiation into Astrocytes
11:42

In vitro Modeling for Neurological Diseases using Direct Conversion from Fibroblasts to Neuronal Progenitor Cells and Differentiation into Astrocytes

Published on: June 10, 2021

4.9K

Area of Science:

  • Neuroscience
  • Regenerative Medicine
  • Stem Cell Biology

Background:

  • Parkinson's disease involves progressive loss of dopaminergic neurons.
  • Previous cell replacement therapies faced ethical concerns and tumor risks.
  • New strategies aim to overcome these limitations for effective Parkinson's treatment.

Purpose of the Study:

  • To review the current status of cell reprogramming for Parkinson's disease.
  • To focus on induced pluripotent stem cells (iPSCs) and direct reprogramming techniques.
  • To discuss preclinical and clinical advancements and associated challenges.

Main Methods:

  • Review of existing literature on cell reprogramming in Parkinson's disease models.
  • Analysis of induced pluripotent stem cell (iPSC) therapy, including preclinical and clinical data.
  • Examination of direct reprogramming of fibroblasts and astrocytes into neurons.
  • Discussion of in vivo reprogramming controversies.

Main Results:

  • Both iPSCs and direct reprogramming show promise for Parkinson's disease treatment.
  • iPSC therapy has advanced through preclinical animal models and early clinical research.
  • Direct reprogramming offers a potential alternative, bypassing ethical and safety concerns.
  • Ongoing research addresses ethical considerations and tumor formation risks.

Conclusions:

  • Cell reprogramming strategies, including iPSCs and direct reprogramming, represent a significant advancement in Parkinson's disease therapy.
  • These methods offer potential solutions to overcome limitations of traditional cell replacement therapies.
  • Further research and clinical trials are necessary to fully establish the safety and efficacy of cell reprogramming for Parkinson's disease.